ol and pentoxifylline
in the medical management of symptomatic PAD.93,94
Pentoxifylline was the ﬁrst drug approved by the FDA for
IC in 1984. By reducing blood viscosity and retarding platelet
aggregation, pentoxifylline use results in improved blood ﬂow
and enhanced tissue oxygenation in affected areas. Porter
et al91 revealed its effectiveness compared with placebo in a